Objectives: A wide variety of extrinsic and intrinsic risk factors may play a role in the development of psoriasis, a long-lasting systemic inflammatory disease. In multiple tissues, the proteins known as (S100) perform a few different activities. Basal epidermal keratinocytes' cytoplasm and the cell periphery of spinous layer cells both contain S100A11. It occurs in regular human keratinocytes in culture. The present investigation was to contrast the blood calgizzarin levels of individuals with psoriasis against those in normal people and to determine whether there was an association between the levels and the degree of severity of the condition.
Methods and materials: Forty individuals with psoriasis enrolled in this case-control clinical trial, while a control group of forty individuals in good health who had been assigned for age and sex provided a standard for comparison. The patients underwent PASI score assessment and serum calgizzarin levels were assessed through ELISA technique.
Results: Calgizzarin serum levels were considerably higher in psoriasis patients compared to the control group (p=0.037). In comparison to male individuals who had psoriasis, substantially increased blood levels of calgizzarin were found in female patients. (p=0.044). According to the degree of severity of the disorder determined by the PASI score, the mean of the calgizzarin levels gradually increased but not substantially. Serum levels of calgizzarin in psoriasis patients did not show any statistically significance relation to the presence of positive family history of the psoriasis, presence of arthropathy, nail affection, psoriasis type, or disease severity.
Conclusion: The current study points out the possibility of involvement of calgizzarin in the etiology of the psoriasis condition. Significantly higher values of serum calgizzarin in females with psoriasis might indicate higher inflammatory state and risks in this patient group.
Limitations: The small sample size is the major limitation of this study.